N/A N=23 Intensive Treatment for Chronic Pain and Posttraumatic Stress Disorder (PTSD)
Stress Disorders, Post-Traumatic
Primary: McGill Pain Questionnaire — 31.91; 30.83 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=137 A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) — 32; 21; 23 percentage of participants
Phase 1 N=70 A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females
Breast Cancer
Primary: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Trastuzumab — 1610; 1800; 1350; 2500 days•μg/mL
N/A N=57 Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects
Alcohol Dependence
Primary: Visual Analog Scales of Similarity to Alcohol - Baseline — 0.18; 0.05; 0.25; 0.04 units on a scale
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Brain Tumors
Refractory Brain Tumors
Primary: Number of Participants With Objective Response — 4; 5; 12; 10 Participants
Phase 2 N=216 Polypill For Prevention of Cardiovascular Disease
Cardiovascular Disease
Primary: Reduction of the Estimated 10-year Total Cardiovascular Risk Score — 11.5; 11.1 percent
Phase 3 N=161 Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia
Hyponatremia
Primary: Hospital Acquired Hyponatremia — 10; 11; 1 participants
Phase 2 N=12 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
Visual Pathway Glioma
Primary: Number of Participants With Objective Response — 2; 2; 3; 1 Participants
Phase 4 N=66 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Cancer
Primary: NRS (Numeric Rating Scale) — -1.29 units on a scale
Phase 3 N=23 Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence
Cocaine Dependence
Primary: Cocaine Urine Toxicology
N/A N=56 The Therapeutic Workplace Initiation Study
Cocaine-Related Disorders · Opioid-Related Disorders · Heroin Dependence
Primary: Cocaine Abstinence — 29; 10 percentage of cocaine negative — p=.004
Phase 2 N=27 Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
Anaplastic Astrocytoma
Primary: Number of Participants With Objective Response — 2; 3; 6; 10 Participants
Phase 2 N=35 Breast Cancer Risk Biomarkers in Postmenopausal Women
Breast Cancer
Primary: The Proportion of Subjects That Complete Intervention of Lovaza™ 4 Grams Per Day — 0.97 proportion of enrolled participants
N/A N=51 Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1
Alcohol Use · Drug Use · Risk Behavior
Primary: Percentage of Monthly Urine Samples That Are Negative for Cocaine — 51.8; 79.3 percentage of urine samples — p=.004
Phase 3 N=18 Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
Behcet's Disease · Behcet Syndrome · Neuro-Behcet's Disease
Primary: Percentage of Participants With Complete Response at Week 30 — 54.5; 0; 100; 100 percentage of Complete Responders